The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor by Lau, C. S. & Belch, J. J. F.
Short Communication
Mediators of Inflammation, 1, 141-143 (1992)
TENIDAP, a new anti-inflammatory drug, is presently
undergoing clinical studies as a treatment for rheumatoid
arthritis (RA). Early pilot work has shown it to be of some
benefit. Tenidap is a dual inhibitor of cyclo-oxygenase and
5-1ipoxygenase enzymes. It has also been shown to modify
white blood cell behaviour such as interleukin-1
production, monocyte differentiation and neutrophil
degranulation. As free radicals (FRs) have been implicated
in the pathogenesis ofRA, we used an in vitro assay system
developed by Misra and Fridovich to assess if tenidap has
FR scavenging effects. Our study shows, for the first time,
that tenidap has general FR scavenging effects although
no effect on the superoxide anion (O-) could be
demonstrated. This effect occurred in a dose-dependent
manner at concentrations above 20 #g/ml (p < 0.005,
Mann-Whitney U-test). As the therapeutic range oftenidap
in serum is between 15 and 30 #g/ml such FR scavenging
activity may be clinically relevant in the treatment of RA.
Ex vivo confirmation of this possibility is underway.
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Introduction
Although the pathophysiology of rheumatoid
arthritis (RA) is not fully understood, certain
mediators have been shown to be important in the
development of inflammation. The role of prosta-
glandins (PGs), metabolites of arachidonic acid
(AA) via the action of cyclo-oxygenase (CO), is well
established. Recently, leukotrienes (LTs), 5-
lipoxygenase (5-LP) metabolites of AA, have also
been shown to be involved in the inflammatory
reactions in RA.
2 Additionally, previous studies
have shown reactive oxygen free radicals (FRs) may
be important in the development of inflammatory
synovitis. - Non-steroidal anti-inflammatory drugs (NSAIs)
are widely used in RA and other inflammatory
arthropathies. They reduce inflammation via their
ability to inhibit CO. However, most NSAIs at
therapeutic levels do not affect LT synthesis. Dual
inhibitors of CO and 5-LP might therefore be
expected to be superior to CO inhibitors alone and
such agents may offer therapeutic advantages in
patients with RA. Tenidap sodium, a novel
anti-inflammatory agent, has been shown to have
combined CO and 5-LP inhibitory activity
4 and has
been reported to be ecacious in short-term studies
of patients with RA. Another study has shown
tenidap to inhibit in vitro activation of human
neutrophil collagenase partly due to interference
with the production of superoxide radicals
(O-).
6 The mechanism of inhibition of O-pro-
duction by tenidap is not fully understood although
the authors suggested that this may be a secondary
phenomenon related to the inhibition of the signal
transduction pathway in the neutrophil rather than
a direct interaction between tenidap and O;.-.
However, if tenidap has antioxidant properties it
may be of further therapeutic advantage in patients
with RA. For this reason we used an in vitro assay
to assess if tenidap was capable of scavenging in
vitro production of O;.- and other general FRs.
Methods
The in vitro assay used in this experiment was
originally developed by Misra and Fridovich
7 for
the estimation of superoxide dismutase (SOD)
activity but it may also be used to differentiate
between specific O- and general FR scavenging
activity. This assay is based on the photo-oxidation
of o-dianisidine (DH2) sensitized by riboflavin (Rb)
(Fig. 1). Rb absorbs a photon and becomes
electronically excited (Rb*). Rb* oxidizes DH2 and
this leads to the formation of flavin semiquinone
(RbH) and the dianisidine radical (DH’). DH" is
then involved in further reactions. It may either
dismute to yield divalently oxidized dianisidine (D),
which absorbs at 460 nm and is measurable by an
ultraviolet/visible spectrophotometer, or be re-
duced by O;.- ion to form DH2 and oxygen (O2).
The O;.- ion involved in the latter reaction is
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FIG. 1. Photo-oxidation of o-dianisidine. DH2--dianisidine; DH’---diani-
sidine radical; D--oxidized dianisidine (measurable at 460nm);
Rb---riboflavin; Rb*---excited riboflavin; RbH--flavin semiquinone;
hvnergy of photon of light; H+--hydrogen ion; O2--oxygen;
O---superoxide anion.
supplied by the reduction of 02 by RbH. Thus, an
agent with O- scavenging activity will divert
DH to the oxidative reaction with enhanced
formation of D, thereby increasing the absorbance
at 460 nm. On the other hand, a general radical
scavenging agent will remove DH’, which reduces
the formation of D, thereby decreasing the
absorbance at 460 nm.
Assay procedure:
Control sample. Sixty /1 of DH2 was added
to a cuvette containing 2.94 ml of Rb solution.
Absorbance of light was measured at 460 nm using
a Philips PU 8680 VIS/NIR kinetics spectropho-
tometer. The cuvette was then placed inside the
illumination box for 4 min after which absorbance
was measured again at 460 nm. The change in
absorbance of this solution was used as the control
and was referred to as zero per cent inhibition on
the assay.
Tenidap sample. Sixty /,1 of tenidap solution was
added to 2.88 ml of Rb solution followed by 60 #1
ofDH2 solution and the measurements were carried
out as above. Each measurement was repeated on
six occasions and percentage inhibition on the assay
was calculated at each occasion. Final concentra-
tions of tenidap at 5, 10, 15, 20, 22.5, 25, 30, 35,
40, 50 and 60 #g/ml were used.
Statistical analysis: The Mann-Whitney U-test was
used to analyse differences between data obtained
from the control sample and those from the tenidap
samples. A p-value of <0.05 was considered
statistically significant.
Materials: Tenidap sodium (CP-66,248) (Fig. 2) was
obtained from Pfizer Central Research (Sandwich
UK). Riboflavin and o-dianisidine were purchased
from Sigma Chemicals Ltd. Riboflavin solution
(1.3 x 10-s M) was prepared in 0.01 M potassium
phosphate buffer, pH 7.5, and o-dianisidine solution
(10
-2 M) was prepared in ethanol. Tenidap was
dissolved in 0.01 M potassium phosphate buffer
solution.
Illumination for the photochemical reaction was
provided by a pair of parallel 10 watt white
fluorescent tubes mounted 15cm apart in an
open-ended box lined with aluminium foil. These
tubes provided a constant source of wide-band
radiation.
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FIG. 2. The molecular structure of tenidap [5-chloro-2,3-dihydro-2-oxo-3-
(2-th enylcarbonyl)-indole-1-carboxam ide].
Results
Figure 3 shows the mean (SEM) percentage
inhibition on the assay by increasing doses of
tenidap. Absorption at 460nm was decreased
significantly when the final concentrations of
tenidap were above 20/g/ml. The higher the
concentration of tenidap, the greater the inhibition
(all p < 0.005).
Discussion
This study shows, for the first time, that tenidap
is a general radical scavenger. We show that it has
no effect on ()- but it has general radical
50
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FIG. 3. Percentage inhibition on the assay by tenidap. Results are
expressed as mean (SEM).
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scavenging effects which are dose-related at final
concentrations above 20 #g/ml. This may explain
its apparent usefulness in RA, as the therapeutic
range of tenidap sodium concentrations in serum is
between 15 and 30/,g/ml (Pfizer Central Research).
The use of the in vitro assay of Misra and
Fridovich to assess FR scavenging properties of
other therapeutic agents has been validated
previously. For example, the FR scavenging effects
of captopril, an angiotensin converting enzyme
inhibitor, and gliclazide, a sulphonylurea hypogly-
caemic agent, have been confirmed using this
assay. 8’9 However, this assay system does not
demonstrate which part of the test molecule is
responsible for its FR scavenging effect. FRs are
chemical species (molecule or atom) with an
unpaired electron which renders them reactive. In
order to achieve a more stable state, FRs try to
accept or donate electrons to other compounds.
Both captopril, which possesses a sulphydryl group,
and gliclazide, with an azabicyclo-octyl ring, are
capable of accepting an electron and undergoing
conformational changes, thus stabilizing the re-
active FRs. It is possible that the carbonyl or
carboxamide structure on the tenidap molecule has
similar reducing properties and inhibits the
production of DH" by accepting an electron from
the excited riboflavin. However, further in vitro
studies are required to confirm this hypothesis.
Free radicals are thought to play an important
role, both directly and indirectly, in the inflam-
matory process.
1 There is now much evidence
supporting a pathological role of oxygen FRs in
RA. For example, cells that are present in the
inflamed joint, such as macrophages, neutrophils,
lymphocytes and endothelial cells are all capable of
producing FRs when isolated. FRs have been
shown in in vitro and animal studies to cause damage
to cartilage cells and inhibit a proteoglycan
synthesis. In patients with RA, products of
oxidative damage are found in serum and synovial
fluid and have been shown to correlate with
disease activity.
11
In conclusion, tenidap is a new anti-inflammatory
drug which, unlike other ordinary NSAIs, has
additional chemical properties including the inhibi-
tion of 5-LP4 and neutrophil release reactions. 5’6
Other authors have also shown it to inhibit the
synthesis of interleukin-1.12 Our study suggests that
tenidap has further therapeutic properties with an
ability to scavenge FRs which may be of relevance
in preventing tissue injury in RA. Such activity is
particularly interesting as previous in vitro studies
have shown 5-LP products, in particular LTB4, to
be reactive towards FRs, and it has been suggested
that such reactivity may partly explain the
chemotactic activity exhibited by LTs.
13 An ex
vivo study of the effects of tenidap on FR activity in
patients with RA is currently underway in a
double-blind study. The correlation between
tenidap’s effects on RA activity, and the production
and removal of FRs will be assessed. It is hoped
that results from this study will improve our
understanding of the pathophysiological role of free
radicals in rheumatoid arthritis.
References
1. ttiggs GA, Moncada S, Vane JR. Eicosanoids in Inflammation. Ann Clin
Res 1984; 16: 287-299.
2. Belch jjF. Eicosanoids and Rheumatology: Inflammatory and vascular
aspects. Prostaglandins, Leukotrienes and Essential Fatty Acids 1989; 36: 219-
234.
3. Merry P, Winyard PG, Morris cj, Grootveld M, Blake DR. Oxygen Free
Radical, Inflammation, and Synovitis: The current status. Ann Rheun. Dis
1989; 48: 864-870.
4. Moilanen E, Alanko J, Asmawi MZ, Vapaatalo H. CP-66,248, New
Anti-inflammatory Agent, is Potent Inhibitor of Leukotriene B and
Prostanoid Synthesis in Human Polymorphonuclear Leucocytes in vitro.
Eicosanoids 1988 1: 35-39.
5. Smith DM, Johnson JA, Loeser R, Turner RA. Evaluation of Tenidap
(CP-66,248) Human Neutrophil Arachidonic Acid Metabolism,
Chemotactic Potential and Clinical Efficacy in the Treatment of Rheumatoid
Arthritis. Agents& Actions 1990; 31: 102-109.
6. Blackburn WD, Loose DL, Heck LW, Chatham WW. Tenidap, in Contrast
to Several Available Nonsteroidal Antiinflammatory Drugs, Potently Inhibits
the Release of Activated Neutrophil Collagenase. Arthritis Rheun.
1991 34(2): 211-216.
7. Misra HP, Fridovich I. Superoxide Dismutase: A photochemical
augmentation assay. Arch Biochen. Biophys 1977;187:303-307.
8. Chopra M, Scott N, McMurray J, McLay J, Bridges A, Smith WE, Belch
jjF. Captopril: A free radical scavenger. Br J Clin Pharn.aco11989: 27: 396-
399.
9. Scott NA, Jennings PE, Brown J, Belch jjF. Gliclazide: A general free
radical scavenger. Eur J Pharn.acol 1991:208: 175- 177.
10. Dormandy TL. An Approach to Free Radicals. Lancet 1983; ii: 1010--1013.
11. Rowley DA, Gutteridge JMC, Blake DR, Farr M, Halliwell B. Lipid
Peroxidation in Rheumatoid Arthritis: Thiobarbituric acid-reactive material
and catalytic iron salt in synovial fluid from rheumatoid patients. Clin Sci
1984; 66: 691--695.
12. MacDonald B, Loose L, Rosenwasser I,J. The Influence of Novel
Arachidonate Inhibitor, CP-66,248, the Production and Activity of
Human Monocyte IL-1. Arthritis Rheun. 1988; 31(4, Suppl): $17.
13. Chopra M, Belch jjF, Smith WE. A Comparison of the Free Radical
Scavenging Activity of Leukotrienes and Prostaglandins. Free Rad Res Con*n.s
1988;5(2): 95--99.
ACKNOWLEDGEMENTS. We grateful to Pfizer Central Research
(Sandwich UK) for financial support and for tenidap sodium. JB is supported
by the Sir John Fisher Foundation.
Received 18 October 1991
accepted in revised form 6 February 1992
Mediators of Inflammation. Vol 1992 143